ReviewCureus2025
KCNT1 (Slack/Slo2.2) and KCNT2 (Slick/Slo2.1) Dysregulation in Intellectual Disability and Behavioral Phenotypes: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potassium channels, particularly the sodium-activated Slo2 (Slack/KCNT1) channels, play a critical role in regulating neuronal excitability and protein synthesis. Emerging evidence suggests a strong association between Slo2 channel dysfunction and the development of intellectual disability (ID), including conditions like Fragile X syndrome and early-onset epileptic encephalopathies. This systematic review was designed and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Studies focusing on molecular, genetic, physiological, or clinical aspects of Slo2 channel function, regulation, or associated disorders were considered. A comprehensive literature search was conducted across multiple electronic databases: PubMed, Europe PubMed Central, Semantic Scholar, Directory of Open Access Journals (DOAJ), ScienceDirect, and Google Scholar. Search terms combined keywords and Medical Subject Headings (MeSH) relevant to Slo2 channels, KCNT1/KCNT2, sodium-activated potassium channels, ID, and neurological disorders. In total, eight studies met the inclusion criteria and were included in the final synthesis. This systematic review synthesizes findings from eight key studies published between 2010 and 2025, encompassing experimental animal models, narrative reviews, and molecular investigations with full-text availability. Each included study underwent methodological quality assessment using validated critical appraisal tools appropriate to its design. Quality assessments were performed using tools such as AMSTAR 2 applied for systematic reviews, cell study-OHAT-inspired for cell experimental studies, and SYRCLE's RoB for animal studies. The review highlights the dual impact of both gain- and loss-of-function KCNT mutations on cognitive function, with gain-of-function mutations often associated with more severe phenotypes. It further explores the molecular mechanisms involving FMRP and CYFIP1 interactions with Slack channels, implicating dysregulated protein translation as a contributor to ID. The literature shows that Slo2 potassium channels are implicated in ID, with both gain- and loss-of-function mutations contributing to cognitive impairment. The molecular mechanisms linking these mutations to clinical phenotypes remain incompletely defined. The findings support a growing consensus that Slo2 channelopathies represent a significant and under-recognized cause of neurodevelopmental impairment, warranting further translational research and therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.